Northwest Biotherapeutics Reports Improved Financial Results for Q2 2026

Northwest Biotherapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $9.2 million, a decrease from a net loss of $15.4 million in the same period last year. For the six months ended June 30, 2026, the company recorded a net loss of $12.3 million, down from $34.7 million in the prior year. Total revenues for the second quarter were $807,000, significantly higher than $131,000 reported in the same quarter of 2025. For the first half of 2026, revenues reached $1.3 million, compared to $506,000 in the first half of 2025.

The company’s operating expenses for the second quarter were $12.4 million, a reduction from $14.9 million in the prior year. This decline was attributed to decreased research and development costs, which fell to $5.7 million from $7.4 million, primarily due to lower expenses related to the Marketing Authorization Application (MAA) for its DCVax®-L product. General and administrative expenses also decreased to $6.7 million from $7.5 million, reflecting reduced legal costs. The company recognized a settlement gain of $2.25 million during the first half of 2026, contributing to the improved financial performance.

In terms of operational developments, Northwest Biotherapeutics has made significant strides in its clinical programs. The company has completed a Phase 3 clinical trial for its DCVax®-L product aimed at treating glioblastoma and submitted an MAA to the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) in December 2023. The company is also exploring collaborations for faster development and commercialization in various countries, including discussions with a major pharmaceutical company in Saudi Arabia.

As of June 30, 2026, Northwest Biotherapeutics reported total assets of $75.9 million, down from $81.3 million at the end of 2025. Current liabilities decreased to $73.4 million from $91.7 million, primarily due to a reduction in convertible notes at fair value. The company’s stockholders’ deficit improved to $45.2 million from $60.3 million, reflecting the conversion of Series C convertible preferred stock into common shares and the issuance of common stock for cash. The company continues to face challenges in securing adequate capital to fund operations, with management expressing substantial doubt about its ability to continue as a going concern for at least one year from the filing date.

Looking ahead, Northwest Biotherapeutics plans to continue its focus on the regulatory review process for its DCVax®-L product and expand its manufacturing capabilities. The company is also pursuing additional financing options to support its ongoing operations and clinical trials. The recent issuance of a $4.9 million convertible promissory note and a standby equity subscription agreement with Yorkville Advisors are part of its strategy to secure necessary funding.